Free Trial

Kymera Therapeutics Q2 2024 Earnings Report

Kymera Therapeutics logo
$44.23 +0.10 (+0.23%)
As of 04:00 PM Eastern

Kymera Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$0.67

Kymera Therapeutics Revenue Results

Actual Revenue
$25.60 million
Expected Revenue
$12.55 million
Beat/Miss
Beat by +$13.05 million
YoY Revenue Growth
+55.20%

Kymera Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Kymera Therapeutics Earnings Headlines

Kymera Therapeutics
A simple pattern that works in any market
Right when most traders were getting bearish, The All-Weather Pattern signaled something different. Following this setup could've turned every $1,000 into $1,770 in just 48 hours. But here's what really gets me excited... You don't need to be glued to your screen all day, no complex formulas, no guessing. Just wait for a stock to close below The All-Weather Pattern, then check if it opens higher the next morning. That's it. While of course I cannot promise future returns or against losses… I've put together a complete breakdown of how this works, including the new stock that’s tending towards The All-Weather Pattern this week.
Bank of America Securities Remains a Hold on Kymera Therapeutics (KYMR)
Kymera stock surges on product pipeline update
Kymera Therapeutics announces corporate goals for 2025
See More Kymera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kymera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kymera Therapeutics and other key companies, straight to your email.

About Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR), a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

View Kymera Therapeutics Profile

More Earnings Resources from MarketBeat